Pharmafile Logo
Pharmafocus logo
Advanced Search

obinutuzumab

Showing 5 posts of 5 posts found.

NICE approves Roche’s Gazyvaro and Novartis’ Xolair

March 11, 2015
Research and Development, Sales and Marketing Gazyvaro, NICE, Novartis, Roche, Xolair, obinutuzumab, omalizumab

NICE today gave the green light to three new biological drugs, after recommending Roche’s Gazyvaro, GSK’s Arzerra and Novartis’ Xolair …

News
Amgen image

Late-stage successes for Amgen and Roche

February 5, 2015
Sales and Marketing Amgen, Bendamustine, Gazyva, Genentech, Humira, Levact, Napp, Roche, adalimumab, obinutuzumab

Roche and Amgen have both posted successful late-stage trial results that they say will contribute to their applications for regulatory …

News
Roche image

NICE U-turn on Roche leukaemia drug

December 2, 2014
Sales and Marketing Gazyvaro, MabThera, NHS, NICE, Roche, leukaemia, obinutuzumab

NICE has reversed its decision on Roche’s chronic lymphocytic leukaemia (CLL) drug Gazyvaro only two months after rejecting the drug. …

News
Roche image

New Roche leukaemia drug beats rival

July 24, 2013
Research and Development, Sales and Marketing Rituxan, Roche, leukaemia, obinutuzumab

Roche’s next generation leukaemia drug obinutuzumab has beaten the firm’s ageing blood cancer medicine Rituxan in a late-stage trial. The …

News

Roche leukaemia drug granted speedy US review

July 3, 2013
Research and Development, Sales and Marketing CLL, FDA, Roche, leukaemia, obinutuzumab

Roche’s investigational leukaemia drug could be available for US patients by the end of the year as the FDA looks …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025